Clinical Trials Logo
  1. Home
  2. End Stage Renal Disease
  3. NCT00374803

Study of Myfortic in Combination With Tacrolimus and Thymoglobulin in Early Corticosteroid Withdrawal

End Stage Renal Disease (ESRD) Clinical Trial

Official title:
A 12-month, Prospective, Randomized, Single Center, Open Label Pilot Study to Evaluate the Safety and Efficacy of Myfortic in Combination With Tacrolimus and Thymoglobulin in Early Corticosteroid Withdrawal

Clinical Trial Summary

To determine the safety and efficacy of a new formulation of Myfortic in combination with tacrolimus and thymoglobulin.

Clinical Trial Description

Evaluate the safety and efficacy of Myfortic in combination with tacrolimus and anti-thymocyte globulin in an early corticosteroid withdrawal protocol. Secondary objective is to determine the pharmacokinetic-pharmacodynamic profile of Myfortic in a corticosteroid withdrawal protocol. ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00374803
Study type Interventional
Source University of Cincinnati
Contact
Status Completed
Phase Phase 4
Start date April 2006
Completion date January 2008
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05908084 - To Compare the Efficacy and Safety of the HAV With AVF in Female Patients With End-Stage Renal Disease Requiring Hemodialysis Phase 3
Active, not recruiting NCT05309109 - Effect of Medium Cut-Off Hemodialysis on Protein Energy Wasting: The EMCOPEW Study N/A
Not yet recruiting NCT04086212 - Ultrafiltration Efficacy of a PD Solution Containing Icodextrin-Xylitol-Carnitine Phase 2
Completed NCT01783626 - Evaluation of Evodial Hemodialyzer Selectivity Modifications (Evodial +) N/A
Active, not recruiting NCT01693263 - Outcome of BCF Access in Hemodialysis Patients
Completed NCT01219959 - Dianeal, Extraneal, Nutrineal (D-E-N) Versus Dianeal Only in Diabetic Continuous Ambulatory Peritoneal Dialysis (CAPD) Patients Phase 3
Completed NCT02278341 - Roxadustat in the Treatment of Anemia in End Stage Renal Disease (ESRD) Patients on Stable Dialysis Phase 3
Completed NCT02593149 - Product Evaluation for the Effectiveness of the ClearGuard® HD End Cap N/A
Withdrawn NCT02274896 - Bayston Multicenter Antimicrobial PD Catheter Safety Study N/A
Completed NCT04912050 - EXtension of Tablo TrEatmeNt Duration Registry
Recruiting NCT02745340 - Substitution of Acetate by Citrate in the Bicarbonate Based Hemodialysis N/A
Completed NCT02733328 - Assessment of Plasma and NGAL for the Early Prediction of Acute Kidney Injury After Cardiac Surgery in Adults Study
Completed NCT04292184 - Evaluation of Thiosulfate in End Stage Renal Disease and Kidney Transplantation Phase 1
Completed NCT02795286 - Automated Setting of Individualized Sodium Technology N/A
Active, not recruiting NCT02808208 - Autologous Adipose Derived Mesenchymal Stem Cells (AMSC) in Reducing Hemodialysis Arteriovenous Fistula Failure Phase 1/Phase 2
Completed NCT00559767 - Mapping of End Stage Renal Disease Genetic Susceptibility in African Americans by Admixture Linkage Disequilibrium N/A
Completed NCT02433210 - A Clinical Study Comparing Basic Performance and Hemocompatibility of 3 Different Dialyzers in Hemodialysis Patients N/A
Completed NCT01594424 - A Safety Study of Tocilizumab to Improve Transplant Rates in Highly Sensitized Patients Awaiting Kidney Transplantation Phase 1/Phase 2
Completed NCT05610683 - Comparison of the Removal of Uremic Toxins With Medium Cut-off and Super High-flux Vitamin E-coated Dialyzers N/A
Completed NCT03249532 - Effect of Dialysis Techniques on Blood Pressure and Cardiac Function During Dialysis N/A